METFORMIN AS A POTENTIAL PHARMACOLOGIC INTERVENTION TO IMPROVE HEALTHSPAN
2024
Metformin and Healthspan Improvement
publication
Evidence: moderate
Author Information
Author(s): Espinoza Sara
Primary Institution: Cedars-Sinai Medical Center
Hypothesis
Can metformin reduce age-related diseases and improve healthspan in older adults?
Conclusion
Metformin shows promise in potentially reducing frailty and other age-related diseases in older adults.
Supporting Evidence
- Metformin is widely used for type 2 diabetes and has been shown to extend lifespan in preclinical models.
- Observational studies suggest metformin may reduce cancer, cardiovascular disease, dementia, frailty, and all-cause mortality.
- Metformin modulates several hallmarks of aging, including epigenetic modifications and mitochondrial function.
Takeaway
Metformin is a common diabetes medicine that might help older people live healthier lives by preventing diseases.
Methodology
A randomized placebo-controlled clinical trial is being conducted to test metformin's effects on frailty and aging.
Limitations
Few clinical trials have directly examined metformin's effects on healthspan.
Participant Demographics
Older adults with glucose intolerance and those without diabetes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website